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Overview
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Abstract
Cardiovascular disease remains one of the leading causes of death in the United States.
It is estimated that 1 in every 3 American adults suffer from high blood pressure.
Hypertension, a precursor to most cardiovascular diseases, continues to grow at an
alarming rate and is seldom managed carefully. Attempts have been made to manage
hypertension and reduce the morbidity and mortality of the cardiovascular organ
through methods including diets, increased amount of exercise, and medications. Many
commercial drugs have been derived from dihydropyridine due to its antihypertensive
property. Dihydropyridine derivatives work by acting as calcium channel blockers
blocking the intake of calcium ions into the vascular smooth muscle and, to a lesser
extent, cardiac muscles. Dihydropyridine moiety is well-known in pharmacology
as L-type calcium channel blockers, which is extremely important since it treats
hypertension in people who suffer from it. It is also highly important to understand
the antagonists of calcium in the arterial hypertension. A brief overview is presented
in this mini-review.
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Introduction

pumped through them. It is estimated that 75 million Americans,
1 in 3 adults, suffers from hypertension. Of that number, only 54%
have their condition under control. Only in 2014, there were over
410,000 American deaths in which high blood pressure was the
primary or contributing factor to the cause of death [20]. This
mini-review highlights the role of dihydropyridine derivatives
as potential drugs to manage hypertension and the diseases
associated with it.

Several heterocyclic compounds (both synthetic and natural)
are widely known and many of them possess significant biological
activities [1-5]. In 2013, four out of top six and nine out of top
twenty one highest selling drugs were small molecule heterocyclic
compounds [6]. Dihydropyridine is one of the important
heterocyclic scaffolds that is frequently found in several medicines
that include, but are not limited to, L-type calcium channel
blocker (antihypertensive) [7-9], N-type channel blocker [10,11],
antianginal [12], antithrombotic [13], antimineralocorticoid [14],
anticonvulsant [15], anti-inflammatory [16,17], anticancer [18],
and analgesic [19]. On the other hand, high blood pressure, also
known as hypertension, is a condition in where a higher than
normal force pushes against the walls of the arteries as blood is

H 3C

O
H3C

Discussion

Cl

Cl
O

O

O
O

N
H

NH2

H3C

In order to a get a clear understanding about the role of
dihydropyridine derivatives in human body it is important to
know the role that L-type calcium channels as well as calcium
channel blockers. A few dihydropyridine derived commercial
drugs are presented in Figure 1.
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Figure 1: Example of a few dihydropyridine-containing antihypertensive commercial drugs.
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L-type calcium channels
Calcium channels are part of plasma membrane proteins that
are made up of calcium selective pores that are opened by a change
in the voltage of the membrane. Calcium channels are found in
neurons, vascular smooth muscles, cardiac muscles, and other
excitable cells. Calcium channels are responsible for a variety
of physiological functions such as neurotransmitter release,
hormone release, muscle contraction, and vasodilation among
other things. Calcium channels play a role in a variety of diseases,
including hypertension [21]. The voltage- dependent calcium ion
channels of the membrane are subdivided into four fundamental
types according to their electrophysiology and sensitivity to
certain drugs and toxins. These channels are called: Channels L,
which has long activation and high conductance. They are mainly
located in skeletal, cardiac and vascular muscle and its function
is contraction. T-channels are transient opening which function
is calcium ion input to negative levels of membrane potential.
N-channels which function is to release transmitters in cerebral
synaptosomes. P-channels which are localized in the cerebellum
cells. Channels A whose characteristics are still being studied. The
L-type, N-type and T-type voltage-dependent calcium channels are
found in the zona glomerulosa in adrenal and the L-type calcium
channels are a specialized type of voltage-gated calcium channel.
Voltage-gated calcium channels selectively permeate calcium ions
into the cell when there is a change from a high voltage to a low
voltage inside of the cell. L-type calcium channels are the primary
route for Ca2+ to enter the cardiac muscles [22].

Calcium channel blockers

Calcium channel blockers (also known as calcium channel
antagonists) are several medications that inhibit the movement
of Ca2+ through calcium channels. There are three main classes of
L-type channel blockers: phenylalkyamines, benzothiazapines,
and 1,4-dihydropyridines. These approved calcium channel
blockers bind to the L-type calcium channels in the cardiac tissue
and smooth muscles. Since the function of the calcium channels
is to regulate the amount of calcium that enters into the cell,
the function of the calcium channel blockers is to prevent the
transmembrane protein from allowing calcium into the cell.
When calcium is allowed into the vascular smooth muscle
and cardiac muscles it causes smooth muscle contraction. People
that suffer from high blood pressure do not want their arteries to
contract because that increases the amount of pressure needed
to circulate the blood in the body which results in an increased
amount of strain placed on the heart and other cardiovascular
organs.

Having calcium channel blockers inhibit the influx of calcium
to the cell results in the relaxation of the vascular smooth muscle
(vasodilation) and decreased systemic vascular resistance which
lowers blood pressure and arterial pressure, which is a major
contributor to chest pain (angina) [23].

Mechanism of action

The presence of calcium is essential for muscle to contract and
according to the different reserve of this ion in the sarcoplasmic
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reticulum of the myofibrils, its absence is noticed with greater
intensity in the smooth muscle than in the myocardium and
the striated muscle. For this reason, the action of the calcium
antagonists is greater on the smooth muscle of the walls.
Although the entry of calcium ions is required for the release
of neurotransmitters, calcium antagonists can directly activate
the release of neurotransmitters through a mechanism that
does not depend on a reflex response. The release takes place
by the opening of storage granules. In this regard, the relative
potency of the calcium antagonists is as follows: felodipine is
greater than nicardipine and it is greater than amlodipine. The
potential clinical relevance of these differences in potency should
never be underestimated because there are many situations
where the discharge of transmitters is far from desirable, such
as in myocardial infraction and heart failure. The binding sites
of calcium with antagonists are heterogeneous. Three sites of
recognition of the dihydropyridines are known, which are accessed
from the extracellular surface of the membrane. To some extent,
the slow onset of the effects of amlodipine and in part its special
pharmacological profile is a consequence of the ionization of the
molecule at normal physiological pH, which prevents its approach
to the binding sites. The participation of calcium ions in smooth
muscle contraction is a well-known phenomenon. Calcium ion can
originate from two different sources: The extracellular calcium
ion, which penetrates fundamentally through the L-type calcium
ion channels and the calcium ion of the intracellular deposits that
is released after receiving the corresponding signal. For example
the neurotransmitter: norepinephrine.
Regardless of the source, calcium ion, known as calcium
activator, binds to a regulatory protein, calmodulin that complexes
with calcium and activates the enzyme protein kinase, which in
turn facilitates the phosphorylation of myosin. The key event is
the phosphorylation of myosin, which comes into contact with
actin and contraction occurs. As the essential characteristic of
hypertension is the increase in peripheral vascular resistance
and since smooth muscle contraction depends on calcium ion, its
antagonists are an effective treatment in this situation provided
that: A considerable proportion of calcium ion, involved in events
that culminate with contraction penetrating into the cytosol
through the channels of calcium ion type L and counteract some
of the other effects of hypertension, such as cardiac hypertrophy
and atherosclerosis.

There are different reasons to argue that excess of calcium
ion entry through the selective calcium ion L-type channels
contributes to the increase in vascular resistance induced by
arterial hypertension. So, intake of calcium ion excess occurs
because the time is prolonged, resulting in an increase in
intercellular deposits of exchangeable calcium ion. In the smooth
muscle cells, the calcium ion tension concentration curve has a
very steep slope, so that little calcium ion is required to trigger an
excessive response. Increased arteriolar tone is counteracted by
the addition of a calcium antagonist. It is admitted that the etiology
of arterial hypertension is very complex and multifactorial,
involving different factors such as: genetic predisposition of the
disease; abnormal operation of the L-type calcium ion channels,
which implies a relative increase in the number of functional
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channels as well as the opening time of each channel. Given all
these elements, it would be very difficult to remove the calcium
antagonists in the list of drugs potentially useful in hypertension,
unless their side effects outweigh their beneficial actions. Calcium
antagonists reduce systolic and diastolic blood pressure without
causing arthrostatic or postural hypertension, without causing
water and sodium retention, without altering the circadian
pattern of blood pressure, without altering the lipid profile in the
plasma, does not retain uric acid nor alter glycaemia. It maintains
or improves renal blood flow and the decrease in blood pressure
they cause does not always lead to a sustained increase in renin
or angiotensin II. However, in the acute phases, plasma levels of
noradrenaline may be increased due to a release of the reflex
stimulated sympathetic neurotransmission in response to the
sudden drop in peripheral vascular resistance and the direct
stimulating effect of the release of noradrenaline from the storage
granules.

The inherit limitations of these drugs are: its negative inotropic
effect; in the case of nifedipine the rapidity of the fall in blood
pressure, which causes reflex achycardia and stimulation of the
sympathetic and renin-agiotensin systems. Prolonged-release
preparations attempt to modify these unwanted responses; the
depressant effect of verapamil, and to a lesser extent, diltiazem on
the conduction system, determines sustained bradycardia in some
cases. The reduced plasma half-life necessitates the administration
of multiple doses, with the exception of amlodipine.

Therapeutic doses are usually associated with side effects
such as constipation, bradycardia, edema. Hypertension is a
vascular disease that is usually accompanied by a decrease, not
an increase, in cardiac output and volume per heartbeat, so it is
logical to choose a calcium antagonist with vascular selectivity
that does not stimulate the release of catecholamine. The
problem would be to know if they are still effective. At present,
antagonists with vascular selectivity share two characteristics:
they all are dihydropyridine derived, and as a consequence of
their selectivity, are a logical alternative in the treatment of
arterial hypertension. However, there are differences between
the different selective vascular drugs, so amlodipine does not
modify plasma noradrenalide, felodipine causes an increase that
persists often in prolonged treatment. In the case of amlodipine,
its hypotensive effect occurs without increasing the heart
rate, whereas felodipine usually produces a reflex tachycardia.
Amlodipine as a consequence of its prolonged plasma half-life and
high bioavailability can be administered in a single dose per day;
On the other hand, its action starts slowly and the possibility of
producing reflex changes in the heart rate is quite remote, does
not produce changes in plasma volume or sodium ion retention,
nor does it present significant alterations in the logogram.
Antagonists with vascular selectivity reduce systemic pressure
by decreasing peripheral vascular resistance and not by changes
in cardiac output or volume depletion. Nifedipine may possibly
meet the requirements of being a selective antagonist by exerting
its best effect on the vessels compared to the myocardium, and
also has no (or very little) effect on nodal tissue or atrioventricular
conduction; The problem is that its selectivity for vessels is
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associated with rapid uptake and plasma distribution, as well
as a rapid rate of fixation to its “receptor” in the complex of the
calcium ion channel, for this reason produces rapid peripheral
vasodilation. As a consequence, the autonomic nervous system
is stimulated, determining a rapid and significant increase of the
heart rate, which forces to concomitant treatment with β-blocker
or a preparation of prolonged release [24-29].

Conclusion

Clinical and laboratory observations of prototypes of calcium
antagonists have revealed some interesting and possibly
unexpected but clinically useful properties of these drugs.
Thus, they are known to interfere with the processes leading to
atherogenic development, to delay left ventricular hypertrophy
induced by hypertension, to inhibit the growth of cancer cells, to
improve the viability of the conserved organs, to protect against
the destructive effect of free radicals and act as antiepileptics
or potentiate the antimalarial effects of chloroquine. These
properties, or at least some of them, should be maintained in the
new generation of dihydropyrine-containing calcium antagonists.
Amlodipine, nitrendipine, felodipine, nisoldipine prolong their
half-life in patients with liver dysfunction. The antagonists
are metabolized in the liver and therefore the dosage must be
carefully adjusted in these cases.
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